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ABSTRACT
Background and aims: The treatment of asthmatic patients is
particularly focused on the control of symptoms as well as
functional and inflammatory parameters. In our study, we
investigated the relationship between the asthma control
test (ACT) which evaluates symptoms and airway inflamma-
tion and functional parameters. 
Materials and methods: Stable asthmatic patients admitted to
our pulmonary outpatient clinic were enrolled in the study
consecutively and underwent the ACT, pulmonary function
tests and methacholine bronchial provocation test (MBPT).
Additionally, fractional exhaled nitric oxide level (FeNO) and
induced sputum cell distribution were assessed. All these
parameters were re-evaluated at the third month after
adjusting medications of the patients according to baseline
ACT scores.
Results: Of the 101 patients screened, we analyzed 83 who
proceeded to the follow up visit. At the baseline visit, 8 were
totally controlled, 36 partially controlled and 39 uncontrolled
according to ACT. At the follow up visit, 10 were totally con-
trolled, 39 partially controlled and 34 uncontrolled.
Comparison of the two visits in terms of all parameters
revealed significant reductions only in the percentages of
patients with MBPT positivity (p = 0.029) and FeNO levels >
20 ppb (p = 0.025) at follow up. The percentages of patients
with FeNO > 20 ppb, MBPT positivity, induced sputum
eosinophilia or induced sputum neutrophilia did not show
significant differences between totally controlled, partially
controlled and uncontrolled groups at both baseline and fol-
low up visits. 
Conclusion: Although the ACT scores did not show significant
correlations with the airway inflammation parameters tested
in this study, a marked reduction in the percentage of
patients with MBPT positivity and FeNO > 20 ppb at follow up
may suggest the importance of the control concept in the
management of asthma.
Keywords: Airway eosinophilia, asthma control test, exhaled
nitric oxide, methacholine bronchial provocation test.
RIASSUNTO 
Razionale e scopo: Il trattamento dei pazienti asmatici si con-
centra in modo particolare sul controllo dei sintomi, paralle-
lamente ai sui parametri funzionali e infiammatori. Nel no-
stro studio abbiamo indagato i rapporti fra l’“asthma control
test” (ACT), che valuta la sintomatologia, con l’infiammazio-
ne delle vie aeree e i parametri funzionali. 
Materiali e metodi: Sono stati arruolati pazienti asmatici con-
secutivi in fase stabile afferenti al nostro ambulatorio di
pneumologia, e sottoposti a compilazione dell’ACT, test di
funzionalità respiratoria, test di provocazione bronchiale con
metacolina (MBPT), misurazione della frazione espiratoria di
ossido nitrico (FeNO) e citologia dell’espettorato indotto.
Tutti questi parametri sono stati rivalutati a tre mesi dopo ag-
giustamento per il trattamento farmacologico sulla base dei
punteggi ACT di base.
Risultati: Su 101 pazienti sottoposti a screening, ne sono stati
valutati 83 che si sono ripresentati alla visita di follow up. Alla
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8 prima visita 8 pazienti erano totalmente controllati, 36 par-
zialmente controllati e 39 non controllati in base all’l’ACT.
Nella visita di follow up, 10 pazienti erano completamente
controllati, 39 parzialmente controllati e 34 non controllati.
La comparazione fra le due visite ha evidenziato, fra tutti i pa-
rametri, una riduzione significativa solo nella percentuale di
pazienti con positività a MBPT (p = 0,029) e livelli di FeNO >
20 ppb (p = 0,025) al follow up. La percentuale di pazienti con
FeNO > 20 ppb, positività al MBPT, eosinofilia neutrofilia
nell’espettorato indotto non hanno mostrato significative
differenze tra i gruppi di pazienti ben controllati, parzialmen-
te controllati e non controllati sia alla prima visita che al fol-
low up. 
Conclusioni: Anche se i punteggi dell’ACT non hanno mostra-
to correlazioni significative con i parametri di infiammazione
delle vie aeree valutati in questo studio, la marcata riduzione
della percentuale di pazienti con positività al MBPT e FeNO >
20 ppb alla visita di follow up può implicare l’importanza del
concetto di controllo nella gestione dell’asma.
Parole chiave: “Asthma control test”, eosinofilia delle vie
aeree, ossido nitrico espirato, test di stimolazione bronchiale
con metacolina.    
INTRODUCTION
Asthma is a chronic disease characterized by in-
flammation of the airways [1]. It has been reported
that the inflammatory process is strongly correlated
to airway hypersensitivity and asthma symptoms.
Monitoring the severity of the disease and treatment
response by evaluating airway inflammation may
enable a better control of the disease [2].
Current guidelines for the diagnosis and treatment
of asthma have particularly focused on managing
asthma according to the control concept rather than
to disease severity as such [3]. Asthma control
should ideally be evaluated in terms of pulmonary
function, inflammatory parameters and quality of
life. It is difficult, expensive and time-consuming to
evaluate all these parameters together in the routine
clinical practice. Thus, simple and rapid methods
are needed to evaluate the asthma control. Several
questionnaires providing numeric values have been
developed to differentiate asthma control levels,
mainly evaluating the clinical control of the pa-
tients. Among the questionnaires approved by 
GINA 2006, the recommended tests are: the
Asthma Control Test (ACT), Asthma Control
Questionnaire (ACQ), and Asthma Therapy
Assessment Questionnaire (ATAQ). ACT which has
been adapted to the Turkish population is easy to
perform [4-7].
The importance of chronic airway inflammation in
asthma has been well documented; clinical symp-
toms and disease severity have been shown to be
related; besides, marked clinical improvement has
been reported via the suppression of inflammation
[8]. In the follow up of inflammation, the evaluation
of sputum eosinophil rates and fractional exhaled
nitric oxide (FeNO) levels have also been recom-
mended along with the monitoring of bronchial 
hyperreactivity [9].
Increased NO levels have been observed in the air-
ways and expired air of asthmatic patients. This in-
crease is attributed to the activity of inducible NO
synthase (iNOS) in the airway epithelial cells and
macrophages [10]. A significant clinical relation-
ship has been demonstrated between FeNO levels
and eosinophilic inflammation [11]; however, a
considerable amount of false negative and positive
findings have been observed [12]. Although FeNO
measurement can provide information about the
disease activity characterized by eosinophilic air-
way inflammation, it is not useful in more severe
disease forms especially in the presence of neu-
trophilic inflammation [13]. FeNO levels of < 35
ppb are accepted as normal values for healthy
adults when measured by standard methods in dif-
ferent populations; however the recommended 
value, after exclusion of extreme values and
atopics, is 20 ppb [14,15]. It is not possible to give
standard normal reference values for asthmatic pa-
tients; thus, individual serial measurements may
provide “stable period” values for asthmatics [13].
Bronchial hyperreactivity (BHR) is one of the most
important characteristics of asthma. BHR measure-
ments can demonstrate variable airflow limitation
objectively. BHR presence has also been shown to
be a risk factor for impaired pulmonary function in
asthmatic patients [16]. Basal methacholine re-
sponse of asthmatic patients can predict the spiro-
metric therapeutic response to inhaled cortico -
steroids [17]. Individual therapies considering BHR
may shorten uncontrolled periods in asthmatic pa-
tients [18]. Thus, BHR has been suggested as a valu-
able indirect marker for asthma control. 
Induced sputum examination has been used as a
non-invasive rapid diagnostic method for determin-
ing airway inflammation [3]. Induced sputum has
been reported to be an objective tool for monitoring
treatment response as well as for assessing asthma
attacks and disease severity in asthmatics [13].
Eosinophilia in induced sputum examination is par-
ticularly useful for predicting the benefit of other in-
flammatory drugs for symptomatic asthmatic pa-
tients, including those on inhaled steroid therapy
[19].
In this study, we aimed to investigate the relation-
ship between ACT - a simple questionnaire for the
evaluation of asthma control - and pulmonary func-
tion, methacholine bronchial provocation test
(MBPT) results, FeNO levels and induced sputum
eosinophilia. We also looked for alterations in these
parameters after adjustment of the treatment regi-
men according to ACT.
MATERIALS AND METHODS
For the present study, 101 consecutive patients aged
between 18 and 65 years who were admitted to our
pulmonary outpatient clinic between 2008 and
2009 with a diagnosis of mild or moderate asthma
according to GINA 2006 criteria were screened. All
patients read and signed the informed consent after
being informed about the study protocol. 
According to the study protocol, a baseline visit was
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treatments were adjusted according to their ACT
scores and patients were asked to come 3 months
later for the follow up visit. At each visit, patients
were questioned about their symptoms of asthma
on the first study day and then they underwent ACT,
measurement of FeNO, pulmonary function tests
and MBPT. Induced sputum investigation was per-
formed 24 hours later.
Asthma control test (ACT)
The ACT is a patient-based 5-item questionnaire
that investigates the disease control [5]. Patients are
questioned about their perception of asthma control
in the previous 4 weeks. For each question there are
five possible answers, with the score ranging from 1
to 5: the total minimum and maximum scores are 5
(poorest asthma control) and 25 (optimal asthma
control), respectively. Depending on the ACT
scores, we classified the patients into three groups
as follows: totally controlled (ACT = 25), partially
controlled (ACT = 20-24) and uncontrolled (ACT ≤
19). Thereafter, the totally controlled and partially
controlled patients were re-grouped as controlled
group (ACT > 19) whereas the uncontrolled patients
remained in the uncontrolled group.
Pulmonary function test
The pulmonary function test was performed in sit-
ting position with nose closed. The test was repeat-
ed three times using a spirometer (Jaeger Master
Screen Pneumo Spirolab II®). Forced expiratory vol-
ume in one second (FEV1), forced vital capacity
(FVC), and the FEV1/FVC ratio were measured ac-
cording to the ATS criteria and the best values were
recorded [20].
Methacholine bronchial provocation test
Patients underwent a methacholine provocation test
according to the 2-min breathing protocol as de-
scribed in ATS guideline. The patients inhaled
methacholine at the doses of 0.0625, 0.125, 0.250,
0.500, 1, 4, 8 and 16 mg/mL after three repetitive
FEV1 measurements. Thereafter, the pulmonary
function test was repeated. The dose which caused
a 20% or more decrease in baseline FEV1 value was
accepted as provocative dose (PD20) [21]. A PD20
value of < 8 mg/mL was accepted as an indicator of
positive BHR.
Measurement of exhaled NO (FeNO) level
Before the spirometric measurements, FeNO level
was assessed during one exhalation (flow rate 0.05
liters/second) using a nitric oxide analyzer (NIOX
MINO Airway Inflammation Monitor; Aerocrine AB;
Solna, Sweden). The unit was expressed as parts per
billion (ppb). The measurement was performed ac-
cording to American Thoracic Society/European
Respiratory Society (ATS/ERS) guidelines. The pa-
tients inhaled ‘NO deficient air’ for 2-3 seconds in
sitting position via a mouthpiece up to the limit of
total lung capacity. Then they were asked to exhale
under a flow rate of 0.06 liters/second against a re-
sistance of 5 cm H2O created by the mouthpiece.
Following the inspiration of free air, the patient fully
exhaled into the apparatus through the mouthpiece.
The nose was not closed, so as to prevent contami-
nation with nasal air during exhalation. Exhalation
period was set over 6 seconds to reach the plateau
concentration [22]. FeNO threshold was accepted
as 20 ppb.
Induction of sputum
After medication with a short-acting β2 agonist, spu-
tum was induced by inhalation of 3% hypertonic
saline by a nebulizer (Pari Master, Pari Respiratory
Equipment Inc. Richmond, VA, USA) with an output
of 0.5 ml/min saline for a maximum period of 20
minutes via a mouthpiece. The patients were encour-
aged to cough and expectorate sputum in a sterile
petri dish 10 minutes after the onset of nebulization
and every 5 minutes. Three flow-volume curves were
obtained before and after each inhalation for patients
with a FEV1 value < 80%. The sputum induction was
terminated when a > 15% FEV1 decrease was ob-
served in comparison to baseline value or when a
symptom occurred. The procedure was terminated
before 20 minutes if the nebulization was sufficient
and sputum was appropriate [23,24].
Processing of sputum
All samples were processed within 2 hours accord-
ing to a method modified from Popov et al. [23,24].
All viscid or denser portions from the expectorated
sample were selected using the “plug selection”
method, placed in an eppendorf tube and weighed.
Dithiothreitol (DTT; Sigma) was freshly prepared
with a dilution of 1:10 with distilled water and
added at a volume equal to two times the weight of
the sample. Then, the sample was mixed mechani-
cally by 20 times back and forth pipetting.
Afterwards, the sample was placed in a shaking 
water bath at 25° C for 15 min to ensure complete
homogenization. Further dilution was performed
with phosphate buffered saline (PBS) in a volume
equal to the sputum plus DTT and the reaction of
DTT was terminated. Then the suspension was fil-
tered through nylon gauze (52 micrometer), the su-
pernatant was aspirated and the cell pellets were re-
suspended with Roswell Park Memorial Institute
(RPMI) media to achieve a concentration of 10/L.
Finally, one drop was put in each cytocentrifuge
cube and cytocentrifuged at 600 rpm for 10 min-
utes. The cytospins were stained with Giemsa.
Differential cell counts were measured by scanning
slides starting at the top left corner in an undulating
manner from top to bottom using high power (x100)
magnification. Two hundred non-squamous cells
were counted and the results were expressed as a
percentage of total non-squamous cell counts. The
threshold for eosinophilia in induced sputum was
set as 3%.
Medication adjustment
Measures were collected in this cohort at the base-
line and 3-month follow up visit. Based on ACT






























8 sary at baseline by stepping down (reducing the
number or dose of medication used) therapy in con-
trolled patients (ACT = 25), or stepping up (increas-
ing the number or dose of medication used) therapy
for uncontrolled (ACT < 20) and partially controlled
(ACT between 20-24) patients. In some controlled
(ACT = 25) and partially controlled patients (ACT
between 20-24) no therapy adjustment was made.
Statistical analysis
We used a “modified” intent-to-treat analysis and
all participants who completed follow up were an-
alyzed. Student’s paired t test was used to compare
ACT score, FEV1 and FEV1/FVC ratios determined at
baseline and follow up visits. The Wilcoxon signed
rank test was used for the comparison of FeNO lev-
els and sputum neutrophil counts between baseline
and follow up. The McNemar test was used to com-
pare the MBPT positivity and sputum eosinophilia
between baseline and follow up. The ACT score cat-
egories of the patients at baseline and follow up
were compared using the McNemar-Bowker test.
Parameters between patients grouped depending on
their ACT scores were compared using the Chi-
squared test. The correlations between ACT scores
and pulmonary function tests were assessed by the
Pearson test. Correlations between ACT scores and
eosinophil and neutrophil counts in induced spu-
tum were assessed by the Spearman test. Values of
p < 0.05 were regarded as statistically significant.




Among the 101 screened patients, 18 had to be ex-
cluded due to asthma attacks (n = 2), pregnancy (n
= 2) or because lost to follow up (n = 14) at the 3rd
month follow up visit. The participants excluded
were not found statistically significant different from
the analyzed patients in terms of age (p = 0.505),
sex (p = 0.223), FEV1% (p = 0.520), atopy (p =
0.718), smoking history (p = 0.406) or total ACT
score (p = 0.366); so a “modified” intent-to-treat
analysis was performed and the data of 83 patients
were analyzed. 
The mean age of the 83 patients analyzed (13 males
and 70 females) was 42.3 ± 11.4 years. The median
of disease duration was 2 years (range 0.5-22).
Twenty-three percent of the patients were current
smokers, 68% were non-smokers and 9% were ex-
smokers. Nine patients had diabetes mellitus, 16
had cardiovascular disease, 7 had defined promi-
nent atopy and 8 had two or more asthma attacks a
year. None of the patients had other obstructive dis-
eases and all were on medication with inhaled
steroids or inhaled steroids and bronchodilators
which their disease state necessitated.
Asthma control level, pulmonary function tests
and MBPT
At the baseline visit, 8 patients were totally con-
trolled, 36 were partially controlled and 39 were
uncontrolled. The mean ACT score was 18.98 ±
4.59. At the follow up visit, 10 patients were totally
controlled, 39 partially controlled and 34 were un-
controlled. Mean ACT score was 19.65 ± 4.11.
Thus, no significant change was observed between
the two visits in terms of ACT score (p = 0.164)
(Table I).
At the baseline visit, the mean FEV1 was 2.59 ± 0.62
liters (93.9 ± 13.7%). Similarly to ACT scores, no
significant change was observed between the two
visits in terms of pulmonary function tests (FEV1,
FEV1/FVC) (Table I).
Analysis of the relationship between ACT scores
and pulmonary function parameters at baseline visit
showed no significant correlation between ACT and
FEV1(L) (r = -0.003, p = 0.981). 
At the baseline visit, 59% of the patients had a posi -
tive MBPT. MBPT positivity was observed in 62% of
the controlled patients. At baseline, there was no
significant difference among totally controlled, par-
tially controlled and uncontrolled patients in terms
of MBPT positivity (p = 0.852) (Table II). At the fol-
low up visit, MBPT positivity was observed in 45%
of all patients, and in 30% of the controlled pa-
tients. Similarly, there was no significant difference
among totally controlled, partially controlled and
uncontrolled patients in terms of MBPT positivity at
the follow up visit (p = 0.250) (Table II). However,
the percentage of patients with MBPT positivity
showed a statistically significant reduction in the
follow up visit (p = 0.029) (Table I). 
Evaluation of FeNO
At baseline, the median FeNO level of patients was
15 ppb (Table I). Thirty-eight percent of the totally
controlled patients had FeNO levels > 20 ppb. The
proportion of patients with FeNO levels > 20 ppb
did not show significant differences among the
three ACT groups (p = 0.054), being highest in the
partially controlled group (Table II). The mean ACT
scores at baseline did not show any correlation with
FeNO levels (r = 0.111, p = 0.318).
The proportions of patients with FeNO levels > 20
ppb were 21%, 45% and 38% in current smokers,
non-smokers and ex-smokers, respectively (p =
0.189).
At the follow up visit the median of FeNO was 14
ppb (Table I). Although statistically insignificant, the
frequency of the uncontrolled patients with FeNO
levels > 20 ppb was found to be higher than that of
the others (p = 0.381) (Table II). As shown in Table I,
the comparison of the median of FeNO levels ob-
tained at the baseline and follow up visits demon-
strated a statistically significant change (p = 0.025). 
Airway inflammation
At baseline, 62 patients had sputum analysis avail-
able; of these 47 had a sputum sample available at
the third month. Twenty-three percent of these pa-
tients had > 3% eosinophilia and none of the totally
controlled patients had sputum eosinophilia. The
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controlled patients. There was no significant differ-
ence among totally controlled, partially controlled
and uncontrolled patients in terms of induced spu-
tum eosinophilia and induced sputum neutrophil
counts (p = 0.398 and p = 0.490, respectively)
(Table III). Similarly, there was no statistically signif-
icant correlation between baseline ACT scores and
induced sputum eosinophilia or neutrophil counts
(r = -0.084, p = 0.573 and r = -0.123, p = 0.411, 
respectively).
At the follow up visit, 30 patients who gave sputum
were analyzed. Among these, 30% had a sputum
eosinophil percentage of > 3%. The median of spu-
tum neutrophil percentage was 42% in totally con-
trolled patients. There was no significant difference
among totally controlled, partially controlled and
uncontrolled patients in terms of induced sputum
eosinophilia and induced sputum neutrophil counts
(p = 0.644 and p = 0.810, respectively) (Table III).
We could not find any statistically significant
change in induced sputum eosinophilia and neu-
trophil percents at baseline and follow up visits (p =
0.791, p = 0.241 respectively) (Table I).
DISCUSSION
Asthma is a chronic inflammatory disease of the
lower airways that is characterized by bronchial 
hyperreactivity and diffuse reversible airway ob-
be controlled by effective treatment. Guidelines on
asthma control have been based particularly on
clinical and functional evaluations. Currently, mon-
itoring airway inflammation has become one of the
most important targets of asthma control. ACT has
been developed for the clinical evaluation of dis-
ease control, while measurement of FeNO and
eosinophil rates in induced sputum are recom-
mended for the evaluation of inflammation [2,3]. In
this study, we investigated the relationship between
ACT and pulmonary functions, bronchial reactivity,
FeNO level and eosinophilia in induced sputum
and the alterations in these parameters after adjust-
ment of the treatment regimen according to ACT.
TABLE I: ACT SCORES, PULMONARY FUNCTION AND INFLAMMATORY PARAMETERS OF THE STUDY PATIENTS AT THE BASE -
LINE AND FOLLOW UP VISITS
Baseline 3rd month p*
(n = 83) (n = 83)
ACT score (mean ± SD) 18.98 ± 4.59 19.65 ± 4.11 0.164
Control of asthma, n (%) 0.779
Totally controlled 8 (10) 10 (12)
Partially controlled 36 (43) 39 (47)
Uncontrolled 39 (47) 34 (41)
FEV1 (L) (mean ±SD) 2.59 ± 0.62 2.65 ± 0.60 0.162
FEV1 (%) (mean ±SD) 93.9 ± 13.7 93.0 ± 15.8 0.968
FEV1/FVC (%) (mean ±SD) 78.2 ± 6.9 77.7 ± 7.1 0.387
MBPT positivity, n (%) 49 (59) 37 (45) 0.029
FeNO (ppb), median (1st and 3rd quartiles) 15 (11-26) 14 (11-21) 0.025
Elevated induced sputum eosinophil (> 3%), n (%) 11/47 (23) 9/30 (30%) 0.791
Induced sputum neutrophil (%), median (1st and 3rd quartiles) 32 (11-50) 34 (18-56) 0.241
Definition of abbreviations: ACT, asthma control test; FeNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 sec; FVC, forced vital
capacity; MBPT, methacholine bronchial provocation test.
*Significant p values (less than 0.05) are emphasized with bold font.
TABLE II: MBPT POSITIVITY AND FeNO 20 PPB RATES OF THE STUDY PATIENTS GROUPED ACCORDING TO ACT SCORES AT
BASELINE AND FOLLOW UP
Totally controlled Partially controlled Uncontrolled
n % n % n % p
Baseline (n = 8) (n = 36) (n = 39)
MBPT positivity 5 62% 20 56% 24 62% 0.852
FeNO > 20 ppb 3 38% 19 53% 10 25% 0.054
3rd month follow up (n = 10) (n = 39) (n = 34)
MBPT positivity 3 30% 21 54% 13 38% 0.250
FeNO>20 ppb 2 20% 10 26% 13 38% 0.381































We found that controlled patients had less
bronchial reactivity and lower FeNO levels with re-
spect to controls although they were not significant-
ly associated. We also demonstrated significant im-
provements in bronchial reactivity and FeNO levels
at the follow up visit.
According to data from the AIRE and INSPIRE stud-
ies, the asthma control level determined with ques-
tionnaires is not concordant with patients’ own per-
ception [25,26]. The AIRE study showed that only
45% of the asthmatic patients in Turkey have their
asthma under control [27]. Similarly, in our study,
according to ACT scores 53% of the patients had
their asthma under control (ACT score > 19) at the
baseline visit, while at the follow up visit 59% had
asthma under control after therapy adjustment.
Bateman evaluated 3,421 uncontrolled asthma pa-
tients and reported that in the poorly controlled
group at baseline no control was achieved in spite
of high doses of inhaled corticosteroid therapy. This
finding indicates that unless inflammation is not
completely suppressed, control may not be
achieved in some asthmatic patients [4]. In our
study, there was no statistically significant differ-
ence between the ACT scores observed at the base-
line and follow up visits. However, the percentage
of patients controlled showed an increase from
53% to 59%. These rates which are lower than ex-
pected may be due to patients’ weak perception of
their disease state or continuation of the inflamma-
tion at the control visit (after 3 months). Indeed, the
presence of eosinophilia in induced sputum of pa-
tients at the follow up visit (30%) (although only
half of the patients gave sputum appropriate for
analysis) indicates that inflammation is not totally
under control. 
The relationship between signs and symptoms in
asthma patients is generally weak. There are studies
demonstrating no association between the pul-
monary function tests and symptoms of the patients
regardless of the perception level [28]. On the con-
trary, other studies have reported a weak relation-
ship between ACT and FEV1 in patients with asthma
[5,29]. In our study, no statistical significance was
observed between ACT scores and FEV1 at either
baseline or follow up visits. The exact influence of
airway hypersensitivity measurement on the asthma
management is controversial [1]. A study evaluating
bronchial hyperreactivity in asthmatic patients has
shown that 86% of totally controlled patients had
MBPT positivity and suggested that airway inflam-
mation and bronchial hypersensitivity continues
even in a totally controlled state [30]. There are
studies which have shown poor asthma control in
patients with MBPT positivity [31,32]. In our study,
the proportion of patients with positive MBPT
showed a statistically significant decrease within
three months of follow up and treatment. When the
association between asthma control level and
MBPT positivity was analyzed, MBPT positivity was
observed in 62%, 56% and 62% of the totally con-
trolled, partially controlled and uncontrolled pa-
tients at the baseline visit. At the follow up visit,
these figures decreased to 30%, 54% and 38%, re-
spectively. 
In asthmatic patients iNOS is activated via cy-
tokines from inflammatory cells and a high amount
of NO is synthesized [10]. It has been documented
that in asthmatic patients on steroid therapy the
amount of NO given in exhaled air is decreased to
levels of healthy people [33,34]. In a study investi-
gating the impact of FeNO measurement in expired
air on asthma control, it was suggested that anti-in-
flammatory therapies adjusted according to ACT
scores might not be sufficient, although a relation-
ship was observed between ACT scores and FeNO
[32]. Another study which found a relationship be-
tween FeNO level and airway inflammation report-
ed that FeNO might not predict the severity of asth-
ma [35]. In our study, evaluation of patients with
FeNO > 20 ppb among totally controlled, partially
controlled and uncontrolled groups demonstrated
that the percentage of patients with FeNO > 20 ppb
was highest in the partially controlled group 
(p = 0.054). However, it has been reported that
asthmatic patients may have FeNO levels higher
than healthy controls even in stable state. Thus, the
reference values for asthmatic patients may not be
completely accurate [36]. Therefore, a comparison
based on patients’ individual values is recommend-
ed. In our study, a small but significant reduction
was observed in FeNO values at the follow up visit
after therapy adjustment (p = 0.025). 
Smoking is known to be associated with increased
TABLE III: INDUCED SPUTUM PARAMETERS OF THE STUDY PATIENTS GROUPED ACCORDING TO ACT SCORE
Totally controlled Partially controlled Uncontrolled p
Baseline
Induced sputum eosinophil > 3%, 
n/N (%) 0/5 (0) 5/21 (23) 6/21 (29) 0.398
Induced sputum neutrophil (%)
median (1st and 3rd quartiles) 26 (10-44) 22 (9-45) 33 (15-57) 0.490
3rd month follow up 
Induced sputum eosinophil 2/4 (50) 4/15 (27) 3/11 (27) 0.644
> 3% n/N (%)
Induced sputum neutrophil (%) 42 (29-53) 28 (18-56) 46 (18-64) 0.810
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oxidative stress and decreased NO production in
the airways. In a study measuring FeNO 15 minutes
after smoking, FeNO levels were found to be higher
in smoker asthmatic steroid naive patients than
healthy smokers. In both healthy and asthmatic
smokers, FeNO levels were lower than in those who
did not smoke. Smoking causes a rapid decrease in
NO levels [37]. In our study, though statistically in-
significant (p = 0.189), the proportion of patients
with FeNO levels > 20 ppb was markedly lower in
current smokers than non-smokers or ex-smokers
(21% vs. 45% and 38%).
Induced sputum examination in asthmatic patients
is a direct method for evaluating the airways.
Eosinophil percentages have been determined be-
tween 0% to 50% in asthmatic patients depending
on disease severity, presence of attacks and use of
steroids [37,38]. The threshold for the induced spu-
tum eosinophilia was accepted as 2-3% in previous
studies [9,39]. In our study, the threshold was set at
3%. At the baseline visit, 13 out of 62 sputums eval-
uated (21%) had an eosinophil percent higher than
3%. At the follow up visit, 30% (n = 9) of the 30 pa-
tients whose sputums were of sufficient quality to
be evaluated had eosinophilia. Eosinophilia rates
did not show any significant change. However, it is
not appropriate to comment on these results be-
cause the sputum examination was possible in only
half of the patients at the follow up visit. This is one
of the limitations of our study. In a study by Green
et al. the patients with mild or moderate asthma
were treated with standard methods depending on
asthma control level and pulmonary function tests
or according to eosinophil rates in induced sputum.
Number of asthma attacks was observed to de-
crease in those who were treated depending on
sputum eosinophil levels [40]. However, the find-
ings of the studies investigating the relationship be-
tween asthma-related symptoms and eosinophilic
inflammation are controversial [8,41]. In a study on
adult asthmatic patients, no difference in sputum
eosinophil counts was reported between patients in
the intermittent vs. mild/moderate persistent groups
[8]. Sputum eosinophil rates were shown to be sim-
ilar among patients who were classified according
to their symptoms (e.g. without symptoms, with
symptoms less than 3 days/week and with symp-
toms more than 3 days/week) [42]. The reason for
these controversial results could be discrepancies in
the description of disease severity and treatment
regimen. In accordance with previous observations,
we found no statistically significant relationship be-
tween asthma control levels and induced sputum
eosinophil rates in our study patients. Neither was
any significant change found after adjustment of the
treatment regimen.
In conclusion, our evaluation of stable asthmatic
patients revealed that ACT scores had no significant
association with functional and inflammatory para -
meters such as MBPT and induced sputum
eosinophil rates, although controlled patients had
less bronchial reactivity and lower FeNO levels
with respect to uncontrolled patients. Furthermore,
a significant improvement was observed in MBPT
positivity and FeNO levels at the follow up after
treatment adjustment. The reason for this insignifi-
cant association between the asthma control test
and inflammation parameters could be attributed to
different phenotypic characteristics and clinical
states of the disease.
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